These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39026360)

  • 1. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
    Xanthouli P; Uesbeck P; Lorenz HM; Blank N; Eichstaedt CA; Harutyunova S; Egenlauf B; Coghlan JG; Denton CP; Grünig E; Benjamin N
    Arthritis Res Ther; 2024 Jul; 26(1):136. PubMed ID: 39026360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
    Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
    Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR; Burger CD; Bartolome S; Safdar Z; Krowka M; Sood N; Ford HJ; Battarjee WF; Chakinala MM; Gomberg-Maitland M; Hill NS
    J Heart Lung Transplant; 2020 May; 39(5):464-472. PubMed ID: 32008947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
    Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
    Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR; Oudiz RJ; Spence R; Despain D; Dufton C
    Am J Cardiol; 2011 Jul; 108(2):302-7. PubMed ID: 21545989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
    D'Alto M; Romeo E; Argiento P; Paciocco G; Prediletto R; Ghio S; Correale M; Lo Giudice F; Badagliacca R; Greco A; Vizza CD
    J Cardiovasc Med (Hagerstown); 2018 Jan; 19(1):12-17. PubMed ID: 29215546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.
    Takatsuki S; Rosenzweig EB; Zuckerman W; Brady D; Calderbank M; Ivy DD
    Pediatr Pulmonol; 2013 Jan; 48(1):27-34. PubMed ID: 22511577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S; Shirato K; Shimamura R; Iwase T; Aoyagi N; Nakajima H
    Curr Med Res Opin; 2012 Jun; 28(6):1069-76. PubMed ID: 22506623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
    Kuwana M; Blair C; Takahashi T; Langley J; Coghlan JG
    Ann Rheum Dis; 2020 May; 79(5):626-634. PubMed ID: 32161055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report).
    Takahashi T; Hayata S; Kobayashi A; Onaka Y; Ebihara T; Hara T
    Clin Drug Investig; 2018 Mar; 38(3):219-229. PubMed ID: 29282676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).
    Maron BA; Waxman AB; Opotowsky AR; Gillies H; Blair C; Aghamohammadzadeh R; Loscalzo J; Leopold JA
    Am J Cardiol; 2013 Sep; 112(5):720-5. PubMed ID: 23751938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.